News

CVS to boost access to Novo Nordisk's weight loss treatment Wegovy for patients on its drug plans
CVS Health said it will significantly expand access to Novo Nordisk's blockbuster weight loss drug Wegovy for patients ...
pharmaphorum23h
Lilly hit as PBM drops Zepbound, but retains Wegovy
Adding to the pressure is that CVS Health has retained coverage of Zepbound's arch rival Wegovy (semaglutide), sold by Novo ...
Healthcare Dive2d
CVS plans to exit ACA individual exchanges, strikes Wegovy deal with Novo Nordisk
Aetna is once again retreating from the Affordable Care Act market, while its parent company notched a deal with Danish ...
Lilly star weight-loss drug Zepbound faces coverage challenge from CVS Health
Wegovy and Zepbound are part of a wave of obesity medications known as GLP-1 receptor agonists that have soared in popularity ...
CVS Health Partners With Wegovy Maker Novo Nordisk, Hikes 2025 Guidance
CVS Health topped Q1 estimates with $94.59 billion in revenue and raised 2025 EPS outlook to $6.00–$6.20 amid strong Medicare ...
CVS Stock Climbs After Wegovy Deal, Strong 1Q
Shares of CVS Health jumped after the company reported a strong first quarter and agreed to open up access to Novo Nordisk's weight-loss medication at more affordable prices. The stock was up 8.7% at ...
Fierce Pharma2d
In major blow for Lilly, Novo strikes deal giving Wegovy preferred access on CVS Caremark formulary
Starting July 1, Wegovy will become the preferred GLP-1 for obesity treatment on CVS Caremark’s largest commercial template ...
Managed Healthcare Executive2d
CVS Caremark to Place Wegovy as Preferred GLP-1 for Weight Loss
Effective July 1, 2025, CVS Caremark will place Wegovy injection 2.4 mg as preferred on its commercial template formularies.
CVS drops Zepbound from preferred coverage in major blow to Eli Lilly
CVS said it will expand access to blockbuster weight loss drug Wegovy for patients covered by its pharmacy benefit manager, Caremark.